Angiotensin II type 1 receptor blocker telmisartan induces apoptosis and autophagy in adult T‐cell leukemia cells. Issue 5 (13th April 2016)
- Record Type:
- Journal Article
- Title:
- Angiotensin II type 1 receptor blocker telmisartan induces apoptosis and autophagy in adult T‐cell leukemia cells. Issue 5 (13th April 2016)
- Main Title:
- Angiotensin II type 1 receptor blocker telmisartan induces apoptosis and autophagy in adult T‐cell leukemia cells
- Authors:
- Kozako, Tomohiro
Soeda, Shuhei
Yoshimitsu, Makoto
Arima, Naomichi
Kuroki, Ayako
Hirata, Shinya
Tanaka, Hiroaki
Imakyure, Osamu
Tone, Nanako
Honda, Shin‐ichiro
Soeda, Shinji - Abstract:
- Abstract : Adult T‐cell leukemia/lymphoma (ATL), an aggressive T‐cell malignancy that develops after long‐term infection with human T‐cell leukemia virus (HTLV‐1), requires new treatments. Drug repositioning, reuse of a drug previously approved for the treatment of another condition to treat ATL, offers the possibility of reduced time and risk. Among clinically available angiotensin II receptor blockers, telmisartan is well known for its unique ability to activate peroxisome proliferator‐activated receptor‐γ, which plays various roles in lipid metabolism, cellular differentiation, and apoptosis. Here, telmisartan reduced cell viability and enhanced apoptotic cells via caspase activation in ex vivo peripheral blood monocytes from asymptomatic HTLV‐1 carriers (ACs) or via caspase‐independent cell death in acute‐type ATL, which has a poor prognosis. Telmisartan also induced significant growth inhibition and apoptosis in leukemia cell lines via caspase activation, whereas other angiotensin II receptor blockers did not induce cell death. Interestingly, telmisartan increased the LC3‐II‐enriched protein fraction, indicating autophagosome accumulation and autophagy. Thus, telmisartan simultaneously caused caspase activation and autophagy. A hypertension medication with antiproliferation effects on primary and leukemia cells is intriguing. Patients with an early diagnosis of ATL are generally monitored until the disease progresses; thus, suppression of progression from AC andAbstract : Adult T‐cell leukemia/lymphoma (ATL), an aggressive T‐cell malignancy that develops after long‐term infection with human T‐cell leukemia virus (HTLV‐1), requires new treatments. Drug repositioning, reuse of a drug previously approved for the treatment of another condition to treat ATL, offers the possibility of reduced time and risk. Among clinically available angiotensin II receptor blockers, telmisartan is well known for its unique ability to activate peroxisome proliferator‐activated receptor‐γ, which plays various roles in lipid metabolism, cellular differentiation, and apoptosis. Here, telmisartan reduced cell viability and enhanced apoptotic cells via caspase activation in ex vivo peripheral blood monocytes from asymptomatic HTLV‐1 carriers (ACs) or via caspase‐independent cell death in acute‐type ATL, which has a poor prognosis. Telmisartan also induced significant growth inhibition and apoptosis in leukemia cell lines via caspase activation, whereas other angiotensin II receptor blockers did not induce cell death. Interestingly, telmisartan increased the LC3‐II‐enriched protein fraction, indicating autophagosome accumulation and autophagy. Thus, telmisartan simultaneously caused caspase activation and autophagy. A hypertension medication with antiproliferation effects on primary and leukemia cells is intriguing. Patients with an early diagnosis of ATL are generally monitored until the disease progresses; thus, suppression of progression from AC and indolent ATL to acute ATL is important. Our results suggest that telmisartan is highly effective against primary cells and leukemia cell lines in caspase‐dependent and ‐independent manners, and its clinical use may suppress acute transformation and improve prognosis of patients with this mortal disease. This is the first report demonstrating a cell growth‐inhibitory effect of telmisartan in fresh peripheral blood mononuclear cells from leukemia patients. Abstract : Telmisartan reduced cell viability and enhanced apoptotic cells via caspase activation in ex vivo peripheral blood monocytes from asymptomatic HTLV‐1 carriers or via caspase‐independent cell death in acute type ATL. Telmisartan also induced significant growth inhibition and apoptosis in leukemia cell lines via caspase activation. Interestingly, telmisartan increased the LC3‐II‐enriched protein fraction, indicating autophagosome accumulation and autophagy. … (more)
- Is Part Of:
- FEBS open bio. Volume 6:Issue 5(2016)
- Journal:
- FEBS open bio
- Issue:
- Volume 6:Issue 5(2016)
- Issue Display:
- Volume 6, Issue 5 (2016)
- Year:
- 2016
- Volume:
- 6
- Issue:
- 5
- Issue Sort Value:
- 2016-0006-0005-0000
- Page Start:
- 442
- Page End:
- 460
- Publication Date:
- 2016-04-13
- Subjects:
- adult T‐cell leukemia/lymphoma -- apoptosis -- autophagy -- drug repositioning -- human T‐cell leukemia virus‐1 -- telmisartan
Molecular biology -- Periodicals
Cytology -- Periodicals
Life sciences -- Periodicals
Biological Science Disciplines -- Periodicals
Molecular Biology -- Periodicals
Cell Biology -- Periodicals
Cytology
Life sciences
Molecular biology
Periodicals
572.805 - Journal URLs:
- http://febs.onlinelibrary.wiley.com/hub/journal/10.1002/(ISSN)2211-5463/ ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1002/2211-5463.12055 ↗
- Languages:
- English
- ISSNs:
- 2211-5463
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 1957.xml